Myristica lowiana Phytochemicals as Inhibitor of Plasmid Conjugation in Escherichia coli by Kwapong, Awo Afi et al.
Research Article
Myristica lowiana Phytochemicals as Inhibitor of Plasmid
Conjugation in Escherichia coli
Awo Afi Kwapong ,1 Sarah Soares,2 Stephen Ping Teo,2 Paul Stapleton,2
and Simon Gibbons 2,3
1Department of Pharmaceutics and Microbiology, School of Pharmacy, University of Ghana, Ghana
2Research Department of Pharmaceutical and Biological Chemistry, UCL School of Pharmacy, University College London,
29-39 Brunswick Square, London WC1N 1AX, UK
3School of Pharmacy, University of East Anglia, Norwich Research Park, Norwich, Norfolk NR4 7TJ, UK
Correspondence should be addressed to Simon Gibbons; anabasis@mail.com
Received 31 January 2020; Revised 8 May 2020; Accepted 18 May 2020; Published 19 June 2020
Academic Editor: Jairo Kenupp Bastos
Copyright © 2020 Awo Afi Kwapong et al. *is is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Hexane extract and methanol fraction from the stem bark ofMyristica lowiana specifically and significantly inhibited the conjugal
transfer of the IncW plasmid R7K, a plasmid which harbors ampicillin-, streptomycin-, and spectinomycin-resistant genes.
*e transfer of this plasmid via the conjugative pilli of Escherichia coli was reduced by 76.5± 2.0% and 79.0± 1.2% by hexane
extract and methanol fraction of M. lowiana, respectively. *e hexane extract exhibited significant anti-conjugant activity at a
non-cytotoxic concentration of 100mg/L as assessed against adult human dermal fibroblast cells. *e hexane extract and
methanol fraction were screened using phytochemical tests, NMR spectroscopy, IR spectroscopy, and high-resolution elec-
trospray ionization mass spectrometry (HRESIMS) and were found to contain terpenoids, sterols, and fatty acids.
1. Introduction
Currently, antibiotic resistance is a major public health con-
cern, especially since to date there is no known universal
method for reversing drug resistance in microbes and the
world is running out of effective antimicrobials [1, 2]. *ere is
considerable evidence of resistance against almost all existing
classes of antimicrobial agents, namely, the β-lactams, ami-
noglycosides, chloramphenicol, glycopeptides, quinolones,
oxalidinones, sulfonamides, tetracyclines, macrolides, ansa-
mycins, streptogramins, and lipopeptides [3]. Additionally, it
has been predicted that if no antimicrobials or means of re-
versing antimicrobial resistance are found soon, the death toll
for antimicrobial-resistant associated infections may rise to
300million by 2050 [4].*is illustrates the gravity of antibiotic
resistance and the urgent need to address the problem.
All existing antimicrobial agents interfere with essential
bacterial growth and metabolic processes or the integrity of
the cell. Unfortunately, targeting such vital functions intro-
duces selection pressure for resistant strains and promotes
evolution of resistance. *e evidence for this is apparent with
the rise of antibiotic resistance in hospitals and communities,
most notably with organisms such as methicillin-resistant
Staphylococcus aureus, vancomycin-resistant Enterococcus,
carbapenem-resistant Enterobacteriaceae (including Escher-
ichia coli), multidrug-resistant Acinetobacter, drug-resistant
Campylobacter, multidrug-resistant Pseudomonas aeruginosa,
drug-resistant Streptococcus pneumoniae, drug-resistant
Neisseria gonorrhoeae, and multidrug-resistant and extensive
drug-resistant Mycobacterium tuberculosis [5].
A complementary approach of tackling antibiotic or
multidrug resistance is to target bacterial adaptation and
persistence mechanisms such as horizontal DNA transfer,
mutation, antibiotic tolerance, and the production of vir-
ulence factors. Such mechanisms are known to be nones-
sential to the growth of bacteria and as a consequence of this,
Hindawi
Evidence-Based Complementary and Alternative Medicine
Volume 2020, Article ID 1604638, 6 pages
https://doi.org/10.1155/2020/1604638
they are not expected to extensively promote evolution of
bacterial resistance against such complementary mediators
[6]. *e approach of inhibiting bacterial adaptation and
persistence mechanisms and the progress made so far have
been reported by Fernandez-Lopez et. al. [7], Smith and
Romesberg [6], Getino et al. [8], and Getino et al. [9].
In this study, extract and fraction from Myristica low-
iana, a dioecious flowering tree of the family Myristicaceae,
were investigated for their capacities to inhibit plasmid
conjugation in E. coli a process that utilizes bacterial type-IV
secretion systems to transfer genetic material, including
antimicrobial resistance genes, between donor and recipient
cells [10]. In addition, the extract and fraction were inves-
tigated for their antibacterial activities, cytotoxicity, and
their phytochemical constituents.
M. lowiana is commonly found in Southeast Asian
riverine forests. It usually grows up to 7–25 meters in height
and has a dark chocolate or blackish coloured stem bark,
buttress roots, lanceolate olivaceous or brown leaves, cream
rusty coloured flowers, and ellipsoidal-shaped fruits and
seeds [11]. M. lowiana has a characteristic watery red sap,
which oozes out upon cutting its bark and wood. *ere is no
known medicinal use of this plant in the literature, and so
far, it is used mainly for construction purposes. *ere are
also no phytochemical reports on this species, but Myr-
isticaceae plants are well known for essential oils, coumarins,
flavonoids, lignans, acylphenols, alkaloids, polyketides, and
terpenoids [12–15]. Herein, we report on the hexane extract
and methanol fraction of M. lowiana and their phyto-
chemistry and biological activities.
2. Materials and Methods
2.1. PlantMaterial. *e stem bark ofM. lowiana was collected
from St.Matang,Malaysia, inMay 2014. Stephen Teo, amember
of the Forest Department Sarawak identified the species. A
voucher specimen (ST001/14) of this tree has been deposited
within the herbarium at the UCL School of Pharmacy.
2.2. Extraction and Fractionation. Powdered M. lowiana
stem bark (592 g) was subjected to ultrasound-assisted ex-
traction and extracted successively with hexane, chloroform,
and methanol. *e powdered plant material was placed in a
5 L glass beaker and covered with the extracting solvent
(2.5 L), hexane.*is was then placed in an ultrasonic bath for
4 h. *e resulting extract was filtered and dried under
vacuum. *e marc was then dried to remove all residual
solvents. *e procedure was repeated with the dried marc
and chloroform and finally with methanol to obtain extracts
of increasing polarity. *is yielded a 0.7% hexane extract, a
1.1% chloroform extract, and a 2.2% methanol extract. *e
extracts were further fractionated using the solid phase
extraction. Nonpolar extracts were subjected to normal-
phase solid phase extraction (Phenomenex® Strata Silica S1)using a step gradient system, 10% chloroform increments in
hexane. Polar extracts were subjected to reverse-phase solid
phase extraction (Phenomenex® Strata Silica C18) using astep gradient system, 10% methanol increments in water.
2.3. Phytochemical Screening. *e extract and fraction ofM.
lowiana were subjected to qualitative phytochemical
screening as per the standardmethods. For the test of sterols,
the test samples were treated with chloroform and con-
centrated sulphuric acid. A red colouration at the upper
layer and a yellow with green fluorescence at the sulphuric
acid layer indicated the presence of sterols. For the test of
terpenoids, the test samples were treated with acetic an-
hydride and concentrated sulphuric acid; formation of blue
green rings indicated the presence of terpenoids. *e biuret
test was used to test for the presence of amide bonds;
aqueous solutions of the test samples were treated with 2
drops of 2% copper (II) sulphate solution and 1mL of 5%
sodium hydroxide solution. A violet or bluish violet or pink
colouration indicated the presence of amide bonds. For
flavonoids, the test samples were treated with a few drops of
1% lead acetate; a yellowish precipitate indicated the pres-
ence of flavonoids. For saponins, the froth test was used.*e
test samples were diluted with distilled water and shaken;
formation of foam indicated the presence of saponins. For
reducing sugars, Benedict’s test was used. For tannins, the
gelatin test was used where the test samples were treated with
1% gelatin solution containing sodium chloride. Formation
of a white precipitate indicated the presence of tannins.
2.4. General Experimental Procedures. *e 1D- and 2D-
NMR spectra were recorded on a Bruker Avance 500MHz
spectrometer. IR spectra were recorded as a thin-film on a
PerkinElmer Spectrum 100 FT-IR Spectrometer. Mass
spectra were recorded on a Micromass Q-ToF Premier
Tandem Mass Spectrometer.
2.5. Biological Activities
2.5.1. Materials and Reagents. Norfloxacin, tetracycline,
ciprofloxacin, amoxicillin, kanamycin sulphate, nalidixic
acid, streptomycin, novobiocin, gentamicin, amphotericin
B, linoleic acid, dimethylsulfoxide, 3-[4,5-dimethylthiazol-2-
yl]-2,5-diphenyltetrazolium bromide (MTT), trichloroacetic
acid (TCA), acetic acid, Tris buffer, sulforhodamine B (SRB),
RPMI-1640 medium (AutoMod™), L-glutamine, glucose,
bicarbonate of soda, and MOPS [3-(N-morpholino)pro-
panesulfonic acid] buffer were purchased from Sigma-
Aldrich (Poole, UK). Muller Hinton broth (MHB), Luria
Bertani broth (LB), MacConkey agar, nutrient agar, Sabo-
uraud dextrose agar, sodium chloride, sodium hydroxide,
phosphate buffered saline (PBS) and human dermal fibro-
blasts, and adult (HDFa) cells were obtained from Fischer
Scientific UK Ltd. Dulbecco’s Modified Eagle’s Medium
(DMEM), Fetal Bovine Serum (FBS), and nonessential
amino acids were obtained from Gibco. Staphylococcus
aureus XU212, which possesses the TetK tetracycline efflux
pump and mecA gene, was provided by Udo [16]. S. aureus
1199B, which possesses the NorA efflux pump, was provided
by Kaatz [17]. Dr. Paul Stapleton, UCL School of Pharmacy,
provided all other bacterial and fungal strains used in this
study.
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2.5.2. Antibacterial Activity. *e antibacterial activity was
determined using the broth microdilution method as de-
scribed previously [18]. Bacterial strains were cultured on
nutrient agar (Fluka Analytical) and incubated at 37°C for 18
hours. A bacterial suspension equivalent to 5×105 cfu/mL
was added to MHB and the test sample, which had been
serially diluted across the 96 well microtitre plate. MICs were
determined after 18 hours of incubation at 37°C. With the
addition of 20 μL of a 1mg/mLmethanolic solution of MTT,
a colour change of the dye to purple indicated the presence
of growth. *e MIC was defined as the lowest concentration
at which no bacterial growth was observed. MIC values were
determined in duplicate per plate and repeated in at least two
independent experiments.
2.5.3. Antifungal Activity. *e antifungal activity was de-
termined using the broth dilution method as described
previously [19]. Fungal strains were cultured on Sabouraud
dextrose agar plates. A fungal suspension equivalent to
1–5×105 cfu/mL was added to supplemented RPMI-1640
and test sample, which had been serially diluted across the 96
well microtitre plate. Control compounds included the
known antifungal agents itraconazole and amphotericin B.
*e MIC was visually determined under light after incu-
bation at 37°C for 24 hours and 48 hours for C. albicans and
C. tropicalis, respectively. MIC values were determined in
duplicate per plate and repeated in at least two independent
experiments.
2.5.4. Bacterial Strains and Plasmids. Plasmid-containing
donor E. coli strains WP2, K12 J53-2, and K12 JD173 and
recipient E. coli strains ER1793 (streptomycin-resistant) and
JM109 (nalidixic-resistant) were used in the bacterial con-
jugation assays. Conjugative plasmids used were pKM101
(IncN; ampicillin-resistant), TP114 (IncI2; kanamycin-re-
sistant), and R7K (IncW; ampicillin-, streptomycin-, and
spectinomycin-resistant), which were purchased from
Deutsche Sammlung von Mikroorganismen und Zellkul-
turen (DSMZ), and conjugative plasmid pUB307 (IncP;
ampicillin-, kanamycin-, and tetracycline-resistant) was
provided by Prof. Keith Derbyshire, Wadsworth Center,
New York Department of Health.
2.5.5. Bacterial Plasmid Conjugation Inhibition Assay (Liq-
uid Conjugation). *e donor cells with plasmids pKM101,
TP114, and pUB307 were mated with the recipient ER1793,
while plasmid R7K donor cells were mated with the recipient
JM109 in the assay. Conjugation was performed as described
previously [20], with minor modifications. Twenty micro-
liters of predetermined inocula (cfu/mL; Supplementary
Table 1) of donor and recipient was mixed with 160 μL Luria
Bertani (LB) broth and extract or control drug. *is was
incubated at 37°C for 18 hours after which the number of
transconjugants and donor cells were determined using
appropriate antibiotic-containing MacConkey agar plates.
Linoleic acid, a known inhibitor of IncW plasmid conju-
gation, was used as a control in this experiment. *e extract
and fraction were evaluated for anti-conjugant activity at
subinhibitory concentration (one-quarter of their MIC
against E. coli NCTC 10418). Antibiotics and the concen-
trations used in MacConkey agar for positive identification
of donors, recipients, and transconjugants (μg/mL) were
amoxicillin (30), streptomycin sulphate (20), nalidixic acid
(30), and kanamycin sulphate (20 and 30). Conjugation
frequency was calculated as the ratio of total number of
transconjugants (cfu/mL) to the total number of donor (cfu/
mL) and expressed as a percentage relative to the negative
control.*is experiment was performed as duplicate in three
independent experiments and anticonjugation activity has
been reported as mean± standard deviation.
2.5.6. Cytotoxicity Activity. *e sulforhodamine B (SRB)
assay as described previously [21] was adapted for the cy-
totoxicity screening. Adult human dermal fibroblast cells
(HDFa; C-013-5C) were grown at 37°C in a humidified
atmosphere of 5% in a culture flask (75 cm2) which con-
tained Dulbecco’s Modified Eagle’s Medium, modified with
10% FBS, 1% nonessential amino acids, and 0.1% gentamicin
and amphotericin B.*e grown cells were seeded in a 96 well
microtitre plate, and a determined quantity of test samples
was added.*e samples were then incubated for 72 h at 37°C
in 5% CO2. Afterwards, 50 μL of cold 40% W/V trichloro-
acetic acid (TCA) solution was added and incubated for an
hour at 4°C and washed four times with distilled water.
Cultured cells were then stained with 0.4% W/V SRB solution
and left for an hour at room temperature. Afterwards, the
plate was rinsed four times with 1% acetic acid and left for
24 h to dry. Prior to optical density (OD) determination at
510 nm using a microtitre plate reader (Tecan Infinite®M200), 100 μL of 10mM Tris buffer solution was dispensed
into the wells and agitated in an orbital shaker for 5min, to
allow solubilisation of SRB-protein complex. *e percentage
of viable cell was calculated using the following formula:
percentage of viable cell �
ODof test sample − ODof blank
ODof control − ODof blank
× 100.
(1)
*is experiment was performed as triplicate in three
independent experiments, and cytotoxicity has been re-
ported as mean± standard deviation.
2.5.7. Statistical Analyses. *e statistical analyses were
carried out using Excel Data Analysis and GraphPad Prism.
Student’s t-test was used to evaluate the difference between
the control conjugal transfer frequency and the test com-
pounds. Results with p< 0.05 were considered statistically
significant.
3. Results and Discussion
In this study, extracts and fractions from Myristica lowiana
were investigated for their capacities to inhibit plasmid
conjugation in E. coli. Extract and fraction that showed
potent anti-conjugant activity, that is, at least 70% reduction
in the transfer frequency of the any of the test plasmids
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(pKM101, TP114, pUB304 and R7K) was further investi-
gated for their antibacterial activities, cytotoxicity, and
phytochemical constituents. *e hexane fractions, chloro-
form extract and its fractions, and methanol extract and its
other fractions did not exhibit potent anti-conjugant ac-
tivity; hence, these products were not further investigated.
Some of the aforementioned extracts and fractions also
showed no conjugal inhibition, while others showed increase
in the conjugation frequency of the test plasmids. *e
hexane extract and methanol fraction eluted with methanol
and water (9 :1, v/v) were the only products that exhibited
potent anti-conjugant activity.
*e hexane extract (4.14 g) gave rise to an olive green
liquid. Phytochemical screening of this extract revealed the
presence of sterols, terpenoids, and amide bonds. However,
the extract tested negative for tannins, saponins, reducing
sugars, and flavonoids. *e NMR spectra (Supplementary
Figures 1 and 2), HRESIMS (Supplementary Figure 3), and
IR spectrum (Supplementary Figure 4) of the hexane extract
indicated the presence of aromatic and aliphatic groups
attributable to aromatic compounds, terpenoids, and fatty
acids.
*e methanol fraction (24.1mg) was eluted with
methanol and water (9 :1, v/v) to yield a brown solid.
Phytochemical screening of this fraction revealed the
presence of tannins and amide bonds. *is fraction tested
negative for saponins, sterols, reducing sugars, flavonoids,
and terpenoids. *e NMR spectra (Supplementary Figures 5
and 6), HRESIMS (Supplementary Figure 7), and IR spec-
trum (Supplementary Figure 8) of the methanol fraction
indicated the presence of aromatic and aliphatic groups
attributable to aromatic compounds and fatty acids.
*e antibacterial activities (Table 1) revealed that both
hexane extract and methanol fraction had moderate anti-
bacterial activity (32 to 64mg/L) against Gram-positive
bacteria but were not active against Gram-negative organ-
isms. We suggest that the difference in activities against
Gram-positive and Gram-negative bacteria may be due to
the differences in the cell wall and the additional outer
membrane in Gram-negative organisms restricting cell entry
or accumulation of components within the extract and
fraction [22].
*e presence of efflux pumps in Staphylococcus aureus
strains SA-1199B (NorA pump) and XU212 (TetK pump)
did not have any effect on the antibacterial activities of the
hexane extract and methanol fraction. *is indicated that
antimicrobial compounds within the extract and fraction
were not susceptible to these prevalent efflux pumps or that
the target(s) lies externally to the cell.
*e extract and fraction were further screened at a sub-
inhibitory concentration (100mg/L) for anti-conjugal ac-
tivity in Escherichia coli. *is test concentration was used to
ensure that any observed anti-conjugal activity may not be
due to growth inhibition. Both hexane extract and methanol
fraction showed significant anti-conjugal activity against the
transfer of the IncW plasmid R7K, reducing the transfer
frequency by 76.5± 2.0% and 79± 1.2%, respectively (Fig-
ure 1). *e anti-conjugation activities of the extract and
fraction were specific to the IncW plasmid R7K; they did not
significantly inhibit the conjugal transfer of IncN plasmid
pKM101, IncI2 plasmid TP114, and IncP pUB307, rather the
extract and fraction increased the conjugation frequency of
plasmids pKM101 and TP114 by a further 20% or more. We
therefore suspect that the extract and fraction might be
targeting different sites on the conjugation machineries,
which may be plasmid incompatibility group specific; hence,
the difference in activities. *is is plausible, as published
literature has shown component variations in the conju-
gation machineries and the mobilizable (MOB) and mating
pair formation (Mpf) systems between different plasmid
incompatibility groups [8, 9, 23, 24]. *e cytotoxicity studies
of hexane extract and methanol fraction against adult hu-
man dermal fibroblast cells (Supplementary Table 2)
revealed that their cytotoxic-IC50s were 154.0mg/L and
Table 1: Minimum inhibitory concentrations of hexane extract and methanol fraction from M. lowiana.
Strain
MIC (mg/L)
Hexane extract Methanol fraction Ciprofloxacin Tetracycline Norfloxacin Itraconazole Amphotericin B
S. aureus ATCC 25923 32 32 0.5
S. aureus 13373 64 64 0.5
MRSA 346724 32 32 >32 <1
MRSA 274819 64 64 >32 <1
MSSA 346702 32 64 >32 <1
S. aureus 1199Ba 32 32 16 32
S. aureus XU212b 64 64 128
E. faecalis 12697 32 32 1 32
E. coli NCTC 10418 >512 >512 <0.0625 1
P. aeruginosa 599 >512 >512 0.25
P. aeruginosa 10662 >512 >512 0.25
K. pneumoniae 342 >512 >512 >32
K. pneumoniae 17 >512 >512 >32
C. albicans ATCC 66027 512 n.tc 0.125 0.25
C. tropicalis ATCC 750 32 n.tc 0.125 0.25
a S. aureus 1199B overexpresses theNorA efflux pump and possesses a gyrase mutation; both contribute to high level resistance to fluoroquinolones. bS. aureus
XU212 overexpresses a TetK efflux pump that confers resistance to tetracycline and carries themecA gene that gives rise to beta-lactam resistance. cn.t, fraction
not tested.
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92.6mg/L, respectively. A comparison of cytotoxicity of the
extract and fraction with effective anti-conjugative ac-
tivities revealed that the cytotoxic-IC50 level of the hexane
extract was above the concentration (100mg/L) needed to
reduce conjugal transfer of the IncW plasmid R7K by
76.5 ± 2.0%.*is suggested that the hexane extract showed
anti-conjugal activity at a non-toxic concentration. For
the methanol fraction, the cytotoxic-IC50 level was slightly
below the effective anti-conjugation concentration
(100mg/L), which indicates that cytotoxicity may be an
issue for one or more components in the fraction, but
whether there is an association with inhibition of plasmid
transfer is yet to be determined. No antibacterial activity
was observed at a concentration of 512mg/L for the
methanol fraction against Escherichia coli. We propose
that the activities of the extract and fraction might be
through disruption of the conjugative machineries in a
highly specific manner, and the slight variation in their
anti-conjugal activities against IncW plasmid R7K may be
due to the variations in their chemical structure.
*e hexane extract, which exhibited good anti-conjugant
activity at a non-cytotoxic concentration was further eval-
uated against plasmid R7K (IncW) at sub-inhibitory con-
centrations, 16 to 256mg/L. *e results (Figure 2) showed
that the activity of the hexane extract was concentration
dependent and its anti-conjugant activity was comparable to
the known IncW plasmid R7K conjugal inhibitor [7],
linoleic acid, although the activity of the linoleic acid was
slightly more potent. *e anti-conjugant IC50 of the hexane
extract and linoleic acid was found to be 77.8 and 60.5mg/L,
respectively, against the conjugal transfer of IncW plasmid
R7K. Statistically, the activities of both the M. lowiana
hexane extract and linoleic acid were found to be similar
since the corresponding p value (0.68) indicated that their
IC50’s were not significantly different.
4. Conclusion
*ese findings show that M. lowiana possesses potent anti-
conjugant and antimicrobial phytochemicals that are worthy
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Figure 1: *e effect of hexane extract and methanol fraction of M. lowiana on the conjugal transfer of plasmids pKM101 (IncN), TP114
(IncI2), pUB307 (IncP), and R7K (IncW), expressed as a percentage relative to a control (without extract). *e extracts were tested at
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of further explorative investigation. *e development a
potent anti-conjugant molecule and/or new antimicrobial
molecule with a new mechanism of action has the potential
in reducing transfer and spread of resistance and virulence
within important Gram-negative organisms such as E. coli.
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